Search Results

You are looking at 1 - 10 of 71 items for

  • Author: Margaret Tempero x
Clear All Modify Search
Full access

Margaret Tempero

Full access

Margaret Tempero

Full access

Margaret Tempero

Full access

Margaret Tempero

Full access

Margaret A. Tempero

Outcomes for pancreatic cancer are becoming less discouraging with the refinement of molecular profiling, both germline and somatic, and beneficial effects seen with adjuvant chemotherapy. The NCCN Guidelines for Pancreatic Adenocarcinoma reflect these advances, and recommend that clinicians consider germline testing for all patients with pancreatic cancer and consider a molecular analysis for those with metastatic disease. The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it.

Full access

Margaret Tempero

Full access

Margaret Tempero

Full access

Margaret Tempero

Full access

Margaret A. Tempero

Pancreatic cancer remains a vexing treatment challenge, with a cure rate that remains just 7%. Two effective regimens—gemcitabine/nab-paclitaxel and FOLFIRINOX—have improved outcomes and are being used earlier in the disease. However, meaningful differences in outcomes may not be realized without novel strategies. Targeting of the immune system is an active area of research.